Source-grounded facts extracted from Artiva Biotherapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Fred Aslan was appointed as principal financial officer and principal accounting officer at Artiva Biotherapeutics, Inc..
“On May 18, 2026 (the “Effective Date”), Fred Aslan, M.D. resigned as President of the Company in connection with Dr. Miralles’s appointment as President and Head of Research and Development of the Company as described below.”
Thad Huston departed as Chief Financial Officer at Artiva Biotherapeutics, Inc..
“On May 18, 2026, Thad Huston and the Company agreed to Mr. Huston’s separation from his position as Chief Financial Officer and principal financial and accounting officer of the Company, effective May 22, 2026”
Diego Miralles resigned as Director at Artiva Biotherapeutics, Inc..
“On May 18, 2026, Diego Miralles, M.D. resigned as a member of the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), effective May 18, 2026”
Artiva Biotherapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
“Artiva Biotherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2026.”
Artiva Biotherapeutics, Inc. reported the year ended December 31, 2025 results: revenue zero, net income Net loss totaled $83.9 million.
“On March 10, 2026, Artiva Biotherapeutics, Inc. (“Artiva”) issued a press release announcing its financial results for the year ended December 31, 2025.”
Daniel Baker was appointed as Class I Director at Artiva Biotherapeutics, Inc..
“On January 28, 2025, the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel Baker, Ph.D. as (i) a Class I director of the Company, with a term of office expiring at the 2025 annual meeting of stockholders”
Alison Moore was appointed as Class III Director at Artiva Biotherapeutics, Inc..
“appointed Alison Moore, Ph.D. as (i) a Class III director of the Company, with a term of office expiring at the 2027 annual meeting of stockholders and (ii) a member of the Technical Operations Committee of the Board”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.